Gilead Sciences annual shares outstanding
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gilead Sciences Shares Outstanding History (GILD)
Gilead Sciences reported 1.24B shares outstanding at the end of fiscal 2025.
View full Gilead Sciences company overviewGilead Sciences annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.24B | −5.0M | −0.40% |
| 2024 | 2024-12-31 | 1.25B | 0 | 0.00% |
| 2023 | 2023-12-31 | 1.25B | −1.0M | −0.08% |
| 2022 | 2022-12-31 | 1.25B | −7.0M | −0.56% |
| 2021 | 2021-12-31 | 1.25B | 0 | 0.00% |
| 2020 | 2020-12-31 | 1.25B | −12.0M | −0.95% |
| 2019 | 2019-12-31 | 1.27B | −16.0M | −1.25% |
| 2018 | 2018-12-31 | 1.28B | −26.0M | −1.99% |
| 2017 | 2017-12-31 | 1.31B | −2.0M | −0.15% |
| 2016 | 2016-12-31 | 1.31B | −112.0M | −7.88% |
| 2015 | 2015-12-31 | 1.42B | −77.0M | −5.14% |
| 2014 | 2014-12-31 | 1.50B | −35.0M | −2.28% |
| 2013 | 2013-12-31 | 1.53B | 14.8M | +0.98% |
| 2012 | 2012-12-31 | 1.52B | 13.0M | +0.86% |
| 2011 | 2011-12-31 | 1.51B | −97.8M | −6.10% |
| 2010 | 2010-12-31 | 1.60B | −195.5M | −10.86% |
| 2009 | 2009-12-31 | 1.80B | −20.1M | −1.11% |
| 2008 | 2008-12-31 | 1.82B | — | — |
Gilead Sciences quarterly shares outstanding
Q4.08
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.24B | −1.0M | −0.08% |
| Q1 2026 | 2026-03-31 | 1.24B | −3.0M | −0.24% |
| Q4 2025 | 2025-12-31 | 1.24B | −5.0M | −0.40% |
| Q3 2025 | 2025-09-30 | 1.24B | −4.0M | −0.32% |
| Q2 2025 | 2025-06-30 | 1.24B | −4.0M | −0.32% |
| Q1 2025 | 2025-03-31 | 1.25B | −1.0M | −0.08% |
| Q4 2024 | 2024-12-31 | 1.25B | 0 | 0.00% |
| Q3 2024 | 2024-09-30 | 1.25B | −1.0M | −0.08% |
| Q2 2024 | 2024-06-30 | 1.25B | −1.0M | −0.08% |
| Q1 2024 | 2024-03-31 | 1.25B | −2.0M | −0.16% |
| Q4 2023 | 2023-12-31 | 1.25B | −1.0M | −0.08% |
| Q3 2023 | 2023-09-30 | 1.25B | −7.0M | −0.56% |
| Q2 2023 | 2023-06-30 | 1.25B | −7.0M | −0.56% |
| Q1 2023 | 2023-03-31 | 1.25B | −7.0M | −0.56% |
| Q4 2022 | 2022-12-31 | 1.25B | −7.0M | −0.56% |
| Q3 2022 | 2022-09-30 | 1.25B | −1.0M | −0.08% |
| Q2 2022 | 2022-06-30 | 1.25B | 0 | 0.00% |
| Q1 2022 | 2022-03-31 | 1.25B | 1.0M | +0.08% |
| Q4 2021 | 2021-12-31 | 1.25B | 0 | 0.00% |
| Q3 2021 | 2021-09-30 | 1.25B | 2.0M | +0.16% |
| Q2 2021 | 2021-06-30 | 1.25B | 0 | 0.00% |
| Q1 2021 | 2021-03-31 | 1.25B | 0 | 0.00% |
| Q4 2020 | 2020-12-31 | 1.25B | −12.0M | −0.95% |
| Q3 2020 | 2020-09-30 | 1.25B | −13.0M | −1.03% |
| Q2 2020 | 2020-06-30 | 1.25B | −13.0M | −1.03% |
| Q1 2020 | 2020-03-31 | 1.25B | −20.0M | −1.57% |
| Q4 2019 | 2019-12-31 | 1.27B | −16.0M | −1.25% |
| Q3 2019 | 2019-09-30 | 1.27B | −28.0M | −2.16% |
| Q2 2019 | 2019-06-30 | 1.27B | −29.0M | −2.24% |
| Q1 2019 | 2019-03-31 | 1.27B | −26.0M | −2.00% |
| Q4 2018 | 2018-12-31 | 1.28B | −26.0M | −1.99% |
| Q3 2018 | 2018-09-30 | 1.29B | −13.0M | −0.99% |
| Q2 2018 | 2018-06-30 | 1.30B | −10.0M | −0.77% |
| Q1 2018 | 2018-03-31 | 1.30B | −7.0M | −0.54% |
| Q4 2017 | 2017-12-31 | 1.31B | −2.0M | −0.15% |
| Q3 2017 | 2017-09-30 | 1.31B | −15.0M | −1.13% |
| Q2 2017 | 2017-06-30 | 1.31B | −25.0M | −1.88% |
| Q1 2017 | 2017-03-31 | 1.31B | −41.0M | −3.04% |
| Q4 2016 | 2016-12-31 | 1.31B | −112.0M | −7.88% |
| Q3 2016 | 2016-09-30 | 1.32B | −127.0M | −8.76% |
| Q2 2016 | 2016-06-30 | 1.33B | −142.0M | −9.64% |
| Q1 2016 | 2016-03-31 | 1.35B | −129.0M | −8.73% |
| Q4 2015 | 2015-12-31 | 1.42B | −77.0M | −5.14% |
| Q3 2015 | 2015-09-30 | 1.45B | −64.6M | −4.27% |
| Q2 2015 | 2015-06-30 | 1.47B | −53.0M | −3.48% |
| Q1 2015 | 2015-03-31 | 1.48B | −60.6M | −3.94% |
| Q4 2014 | 2014-12-31 | 1.50B | −35.0M | −2.28% |
| Q3 2014 | 2014-09-30 | 1.51B | −20.4M | −1.33% |
| Q2 2014 | 2014-06-30 | 1.53B | −2.8M | −0.19% |
| Q1 2014 | 2014-03-31 | 1.54B | 13.3M | +0.87% |
| Q4 2013 | 2013-12-31 | 1.53B | 14.8M | +0.98% |
| Q3 2013 | 2013-09-30 | 1.53B | 18.2M | +1.20% |
| Q2 2013 | 2013-06-30 | 1.53B | 16.6M | +1.10% |
| Q1 2013 | 2013-03-31 | 1.52B | 8.0M | +0.53% |
| Q4 2012 | 2012-12-31 | 1.52B | 13.0M | +0.86% |
| Q3 2012 | 2012-09-30 | 1.52B | 3.7M | +0.24% |
| Q2 2012 | 2012-06-30 | 1.51B | −40.5M | −2.61% |
| Q1 2012 | 2012-03-31 | 1.52B | −66.6M | −4.20% |
| Q4 2011 | 2011-12-31 | 1.51B | −97.8M | −6.10% |
| Q3 2011 | 2011-09-30 | 1.51B | −118.8M | −7.28% |
| Q2 2011 | 2011-06-30 | 1.55B | — | — |
| Q1 2011 | 2011-03-31 | 1.58B | −220.7M | −12.24% |
| Q4 2010 | 2010-12-31 | 1.60B | −195.5M | −10.86% |
| Q3 2010 | 2010-09-30 | 1.63B | −172.7M | −9.57% |
| Q2 2010 | 2010-07-31 | 1.68B | — | — |
| Q1 2010 | 2010-03-31 | 1.80B | — | — |
| Q4 2009 | 2009-12-31 | 1.80B | −20.1M | −1.11% |
| Q3 2009 | 2009-09-30 | 1.80B | — | — |
| Q2 2009 | 2009-06-30 | 1.81B | — | — |
| Q4 2008 | 2008-12-31 | 1.82B | — | — |
Gilead Sciences Share Buyback History
A share buyback, also called a stock repurchase, is when a company uses cash to buy its own shares. Gilead Sciences share buyback history shows the reported cash used for repurchases. Buybacks can reduce shares outstanding, but issuance, stock-based compensation, acquisitions, and stock splits can change the share count separately.
Gilead Sciences used $1.92B to repurchase common stock in fy 2025. Across the latest 5 reported fiscal years, total share repurchases were $6.01B. The latest reported quarter showed $355.0M of share repurchases.
| Fiscal year | Period ended | Share repurchases |
|---|---|---|
| 2025 | 2025-12-31 | $1.92B |
| 2024 | 2024-12-31 | $1.15B |
| 2023 | 2023-12-31 | $1.00B |
| 2022 | 2022-12-31 | $1.40B |
| 2021 | 2021-12-31 | $546.0M |
| 2020 | 2020-12-31 | $1.58B |
| 2019 | 2019-12-31 | $1.75B |
| 2018 | 2018-12-31 | $2.90B |
| 2017 | 2017-12-31 | $954.0M |
| 2016 | 2016-12-31 | $11.00B |
TickerStat uses SEC-reported cash payments for common-stock repurchases. The amounts describe capital returned through buybacks; they are not a forecast or a measure of the number of shares retired.
Gilead Sciences shares outstanding trends
Over the last five fiscal years, Gilead Sciences's shares outstanding moved from 1.25B to 1.24B, a change of −13.0M. The latest reported quarter, Q2 2026, shows 1.24B.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gilead Sciences source filings ↗Community posts
Gilead raises its sales outlook but projects a deeper acquisition-driven annual loss
Gilead ($GILD) increased its 2026 product-sales forecast to $31.0–$31.3 billion from $30.1–$30.4 billion after third-quarter 2026 product revenue rose 13% to $8.3 billion. HIV sales grew 18% to $6.2 billion, supported by demand, pricing and ...
Gilead agrees $1.275 billion purchase of PepStar's oral inflammation program
Gilead ($GILD) agreed to acquire worldwide rights to PepStar's investigational oral IL-23 receptor inhibitor program, led by HCXT-2001. The agreement calls for $1.275 billion in upfront cash consideration payable at closing, subject to cust ...
